{
  "docId": "019dd923-622b-71dc-a6da-84595e2c37a3",
  "docSlug": "08680a75fcb3",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 74,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a visual comparison of 'Doses Sold' vs 'Doses Used' to illustrate inventory dynamics and management's optimistic outlook.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "bar_chart_grouped",
    "footnote",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/56",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-56",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Management expected doses sold to increase every year after 2023",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-e6ec-7186-b7be-746471cc0bb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.68,
        "x": 0.16,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Anticipated Long-Term Comirnaty U.S. Doses Sold",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bce10a7-dbe7-4bff-ab02-1118845a25d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "paragraph",
      "text": "Despite a significant reduction in COVID-19 sales for 2023, management expected growth to resume in 2024.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09baf8df-6322-4dd3-b5a8-402eefe458e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Importantly, Management Expected 2023 COVID Sales to be the Trough With Sustained Growth Thereafter — Pfizer Q4 2022 Earnings Presentation",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-e6ec-7186-b7be-79e56b1352e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.3,
        "y": 0.16
      },
      "kind": "source-note",
      "text": "Excerpt from Pfizer's Q4 2022 Earnings Presentation",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8d74233-3775-498b-a047-90c82e996654",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.02
      },
      "kind": "title",
      "text": "Importantly, Management Expected 2023 COVID Sales to be the Trough With Sustained Growth Thereafter",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67420694-8d14-41c2-9f4d-0ce413146a64",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "20189987-e0b9-4054-8d59-b2c99f887aa1",
      "evidence": "The slide contrasts management's optimistic growth projections against the reality of a 2023 trough.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07",
      "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.",
      "position": 0,
      "objective": "What are the costs of inaction for Pfizer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 71,
      "from": 11,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f",
      "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.",
      "position": 1,
      "objective": "How can Pfizer improve its performance?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}